In an action relating to amlodipine besylate (Pfizer’s NORVASC), Apotex is seeking relief in the Quebec Superior Court pursuant to the Ontario Statute of Monopolies, U.K. Statute of Monopolies, the Trade-marks Act, and unjust enrichment. Pfizer brought a motion to dismiss Apotex’s claim. On April 25, 2018, the Quebec Superior Court dismissed an application by Pfizer (part of the motion to dismiss) to dismiss the action, finding that the Quebec Superior Court has jurisdiction to adjudicate Apotex’s claim under the Ontario Statute of Monopolies: Apotex Inc c Pfizer Limited, 2018 QCCS 1765. The balance of Pfizer’s motion to dismiss has been deferred to the trial in the liability phase of the proceeding.
Related Publications & Articles
-
Dexlansoprazole formulation patent invalid and not infringed by Apotex
On February 7, 2024, the Federal Court dismissed Takeda’s action under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations in relation to dexlansoprazole (Takeda’s DEXILANT).Read More -
FCA upholds inducement of infringement findings relating to paliperidone palmitate
On January 12, 2024, the Federal Court of Appeal (FCA) dismissed both appeals: Apotex Inc v Janssen Inc, 2024 FCA 9 and Pharmascience Inc v Janssen Inc, 2024 FCA 10.Read More -
Federal Court of Appeal affirms paliperidone palmitate claims are not unpatentable methods of medical treatment
On February 1, 2024, the Federal Court of Appeal (FCA) dismissed Pharmascience’s appeal. Per the FCA, whether a claimed dosing regimen is an unpatentable method of medical treatment cannot be based ex...Read More